Stay updated on SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Sign up to get notified when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.
Latest updates to the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check24 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check53 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check60 days agoChange DetectedThe results of the Phase II trial on sequential pembrolizumab and radiotherapy for locally advanced NSCLC with high PD-L1 expression have been posted, detailing efficacy and safety outcomes, including progression-free survival and overall survival rates.SummaryDifference39%
- Check75 days agoChange DetectedThe website has added new features, while several detailed data fields and options for downloading study information in various formats have been removed.SummaryDifference4%
Stay in the know with updates to SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SPRINT: Personalized Radio-Immunotherapy for NSCLC Clinical Trial page.